Bortezomib Active Not Recruiting Phase 1 Trials for Multiple Myeloma (MM) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01998971A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
NCT01038388A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma